

About Martin and Harris Laboratories Limited Unlisted Shares

- **A)** One of India's oldest and biggest business conglomerates, the "Apeejay Group," includes Martin & Harris Laboratories Ltd, which was established in Gurgaon, Haryana, in 1996. One of the presidents and co-promoters of Apeejay Stya & Svran Group is Mrs. Sushma Paul Berlia. She promotes Martin & Harris Laboratories Ltd.
- **B)** Pharmaceuticals, medical chemicals, and botanical items are manufactured by Martin & Harris Laboratories Ltd. In addition to its primary business, it managed its finances by investing in various ventures that yielded favorable returns, such as mutual funds, listed and unquoted equities, etc. The income contribution from the various business verticals is shown below.

52% of the business is pharma. Investment and derivatives business = 48%

C) The company's units are located in UNA Himachal Pradesh and Roorkee. To comply with worldwide standards, it is continuously modernizing and expanding its manufacturing facilities. **D)** The Director-General of Health Services, Ministry of Health & Family Welfare, Government of India, has given the company the title of "Best Innovative in process & formulation development". has also been awarded the 2018 Pharma Excellence Awards by ASSOCHAM, the peak industry association.

Fundamentals

Fundamentals					
Martin and Harris Laboratories	000 Par Familia Paisa	Market Cap (in cr.)	390		
Unlisted Shares Price	980 Per Equity Price	P/E Ratio	9.74		
Lot Size	50 Shares	P/B Ratio	0.62		
52 Week High	1300	Debt to Equity	0.01		
52 Week Low	980	ROE (%)	6.33		
Depository	NSDL	Book Value	1606.57		
PAN Number	AABCM0832A	Face Value	10		
ISIN Number	INE3VV01015				
CIN Number	U24239HR1993PLC033630	RDS PRO	SPER		
RTA	RCMC Share Registry Pvt. Ltd				

Financials (Figures in cr)

Balance Sheet					
Assets	2021	2022	2023	2024	
Fixed Assets	13	13	15	18	
CWIP	0	0.4	3	0	
Investments	112	373	62	70	
Trade Receivables	0	0	1	2	
Inventory	19	24	19	30	
Other Assets	316	132.6	515	542	
Total Assets	460	543	615		
Liabilities	2021	2022	2023	2024	
Share Capital	3.9	3.99	3.99	3.99	
FV	10	10	10	10	
Reserves	442	523	589	628	
Borrowings	5	5	4	8	
Trade Payables	5	4	10	17	
Other Liabilities	4.1	7.01	8.01	5.01	
Total Liabilities	460	543	615	662	



MARTIN AND HERRIS LABORATORIES LTD.

P&L Statement					
P&L Statement	2021	2022	2023	2024	
Revenue	168	186	205	146	
Cost Of Meterial consumed	64	50	47	41	
Gross Margin	61.9	73.12	77.7	71.92	
Change in Inventory	0	0	0	0	
Employee Benefit Expenses	13	19	25	24	
Other Expenses	31	47	61	55	
EBITDA	60	70	72	26	
OPM	35.71	37.63	35.12	71.81	
Other Income	12	26	24	34	
Finance Cost	0	0.15	0	0.6	
D&A	3	3	4	5	
EBIT	57	67	68	21	
EBIT Margin	33.93	36.02	33.17	14.38	
PBT	69	93	92	55	
PBT Margin	41.7	50	44.88	37.67	
TAX	17	23	24	15	
PAT	52	70	68	40	
NPM	30.95	37.63	33.17	27.4	
EPS	133.33	175.44	70.43	100.25	
Financial Ratios	2021	2022	2023	2024	
Operating Profit Margin	35.71	37.63	35.12	17.81	
Net Profit Margin	30.95	37.63	33.17	27.4	
Earning Par Share (Diluted)	133.33	175.44	70.43	100.25	

Cash-Flow Statement					
Cash- Flow Statement	2021	2022	2023	2024	
PBT	69	93	92	55	
OPBWC	62	79	72	27	
Change in Receivables	18	0	-1.3	-0.6	
Change in Inventories	V 2 0 W	ADF6C D	5.3	-12	
Change in Payables	-6	15	4.5	7	
Other Changes	-206	100.5	-400.5	11.5	
Working Capital Change	-192	96	-392	6	
Cash Generated From Operations	-130	175	-320	33	
Tax	-37	-23	-24	-14	
Cash Flow From Operations	-167	152	-344	19	
Purchase of PPE	-3	-2	-8.2	-12	
Sale of PPE	0	0	0	10	
Cash Flow From Investment	178	-132	325.4	-21	
Borrowing	-8.5	0.7	0.2	4	
Divided	-0.8	-1.4	0	0	
Equity	0	0	-0.14	-1	
Others From Financing	-0.2	0	-1.96	1	
Cash Flow from Financing	-9.5	0.7	-1.94	1	
Net Cash Generated	1.5	19.3	-20.54	-1	
Cash at the Start	0.7	2.3	21.32	0.8	
Cash at the End	2.2	21.6	0.7	-0.2	